Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Absolute monocytosis at diagnosis correlates with survival in diffuse large B‐cell lymphoma—possible link with monocytic myeloid‐derived suppressor cells
Tamar Tadmor, Rona Fell, Aaron Polliack, et al.
Hematological Oncology (2012) Vol. 31, Iss. 2, pp. 65-71
Closed Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Frank Vari, David Arpon, Colm Keane, et al.
Blood (2018) Vol. 131, Iss. 16, pp. 1809-1819
Open Access | Times Cited: 274
Trial watch
Laura Senovilla, Erika Vacchelli, Jérôme Galon, et al.
OncoImmunology (2012) Vol. 1, Iss. 8, pp. 1323-1343
Open Access | Times Cited: 220
Blood CD33(+)HLA-DR(−) myeloid-derived suppressor cells are increased with age and a history of cancer
Chris P. Verschoor, Jennie Johnstone, Jamie Millar, et al.
Journal of Leukocyte Biology (2013) Vol. 93, Iss. 4, pp. 633-637
Open Access | Times Cited: 210
Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models
William K. Decker, Rodrigo Fernandes da Silva, Mayra Hernandez Sanabria, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 198
T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells
Imane Azzaoui, Fabrice Uhel, Delphine Rossille, et al.
Blood (2016) Vol. 128, Iss. 8, pp. 1081-1092
Open Access | Times Cited: 151
Myeloid-derived suppressor cells in hematological malignancies: friends or foes
Meng Lv, Ke Wang, Xiao‐Jun Huang
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 98
Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies
Shifen Wang, Xingyun Zhao, Siwen Wu, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 25
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study
Colm Keane, Frank Vari, Mark Hertzberg, et al.
The Lancet Haematology (2015) Vol. 2, Iss. 10, pp. e445-e455
Closed Access | Times Cited: 87
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era
Tamar Tadmor, Alessia Bari, Stefano Sacchi, et al.
Haematologica (2013) Vol. 99, Iss. 1, pp. 125-130
Open Access | Times Cited: 86
Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells
Veronika Bachanová, Dhifaf Sarhan, Todd E. DeFor, et al.
Cancer Immunology Immunotherapy (2017) Vol. 67, Iss. 3, pp. 483-494
Open Access | Times Cited: 84
Peripheral blood myeloid-derived suppressor cells reflect disease status in idiopathic pulmonary fibrosis
Isis E. Fernandez, Flavia R. Greiffo, Marion Frankenberger, et al.
European Respiratory Journal (2016) Vol. 48, Iss. 4, pp. 1171-1183
Open Access | Times Cited: 70
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin
Shunjie Yu, Xiaotong Ren, Lijuan Li
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 28
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
Gunilla Enblad, Hannah Karlsson, Angelica Loskog
Human Gene Therapy (2015) Vol. 26, Iss. 8, pp. 498-505
Open Access | Times Cited: 58
Myeloid-derived suppressor cells in B cell malignancies
Yaghoub Yazdani, Mousa Mohammadnia‐Afrouzi, Mehdi Yousefi, et al.
Tumor Biology (2015) Vol. 36, Iss. 10, pp. 7339-7353
Closed Access | Times Cited: 54
Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients
Jingwei Jiang, Weijian Guo, Xiaohua Liang
Human Immunology (2014) Vol. 75, Iss. 11, pp. 1128-1137
Closed Access | Times Cited: 53
Myeloid‐Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets
Nikoleta Bizymi, Sunčica Kapor, Astrid Olsnes Kittang, et al.
HemaSphere (2019) Vol. 3, Iss. 1
Open Access | Times Cited: 51
Prognostic impact of monocyte count at presentation in mantle cell lymphoma
Kathrin Aprile von Hohenstaufen, Annarita Conconi, Cassio P. de Campos, et al.
British Journal of Haematology (2013) Vol. 162, Iss. 4, pp. 465-473
Open Access | Times Cited: 48
CD4+ tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy
Colm Keane, Devinder Gill, Frank Vari, et al.
Faculty of Health; Institute of Health and Biomedical Innovation (2013)
Closed Access | Times Cited: 46
Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma—New Therapeutic Targets
Christina Mitteldorf, Arbeneshe Berisha, Monique C. Pfaltz, et al.
The American Journal of Surgical Pathology (2017) Vol. 41, Iss. 7, pp. 998-1004
Open Access | Times Cited: 44
How I investigate monocytosis
David T. Lynch, Jeff Hall, Kathryn Foucar
International Journal of Laboratory Hematology (2018) Vol. 40, Iss. 2, pp. 107-114
Open Access | Times Cited: 40
Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells
Nicola Tumino, Piera Filomena Fiore, Andrea Pelosi, et al.
Seminars in Immunology (2022) Vol. 61-64, pp. 101668-101668
Open Access | Times Cited: 21
Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies
Vaishali Bhardwaj, Stephen M. Ansell
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 11
Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives
S. Rajkumari, Jaspreet Singh, Usha Agrawal, et al.
International Immunopharmacology (2024) Vol. 142, pp. 112949-112949
Closed Access | Times Cited: 4
Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly
A. Betsch, Omer Rutgeerts, S. Fevery, et al.
Blood Reviews (2018) Vol. 32, Iss. 6, pp. 490-498
Closed Access | Times Cited: 33
Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis
Shing Fung Lee, Ting Ying Ng, Devon Spika
BMC Cancer (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top